Improvement of self‐administration experience with a new injection device: Real‐life experience with risankizumab in patients with psoriasis
Skin Research and Technology · 2024-08 · 30 (8)
DOI: 10.1111/srt.13902 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Skin Research and Technology, online erschienen am 20.08.2024. Verfasst von Alexandra Maria Giovanna Brunasso und 8 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Dermatology, Villa Scassi Hospital, ASL3, Genoa, Italy. Hauptthemen laut MEDLINE: Psoriasis, Self Administration. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Trypanophobia or “needle phobia” represents a potential hindrance to the effective management of chronic diseases whenever an injectable therapy might be required, especially in case of frequent administrations. Psoriasis, a chronic dermatologic disease, can be effectively treated with biologic drugs administered subcutaneously. Thankfully, anti‐IL‐23 drugs require few administrations per year and are available in prefilled pens that hide the needle, thus representing a convenient option in patients with trypanophobia.
Methods
An observational multicentric study was conducted on patients with moderate‐to‐severe psoriasis who were treated with 75 mg × 2 risankizumab prefilled syringe therapy for more than 6 months and reported a loss of efficacy measured by the Psoriasis Area and Severity Index (PASI) from PASI 90 to PASI 75 attributed to a reduction of adherence due to trypanophobia. The patients were switched to 1 prefilled pen of risankizumab 150 mg and asked to fill out the Self‐Injection Assessment Questionnaire (SIAQ) before and after the injection at week 0 and at the following administration after 12 weeks. Subjects scored each item of the SIAQ on a 5‐point scale, scores were later transformed from 0 (worst experience) to 10 (best experience).
Results
Twenty‐two patients were enrolled. The mean SIAQ predose domain scores were 5.5 for feelings about injection, 6.2 for self‐confidence, and 6.4 for satisfaction with self‐injection. After dose scores were higher (> 8.5) for each of the six domains at Week 0 and even higher after 12 weeks (> 9.0).
Conclusions
User‐friendly devices, such as prefilled pens, and a lower number of injections improved patient satisfaction in a group of patients with psoriasis on treatment with biologic drugs. We believe that treatment adherence could be positively influenced by such changes in the way of administration of a biologic treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Dermatology, Villa Scassi Hospital, ASL3, Genoa, Italy.
- Section of Dermatology, Department of Health Sciences (DiSSal), University of Genoa, Genoa, Italy.
- IRCCS San Martino University Hospital, Genoa, Italy.
- Division of Dermatology, EO Galliera, Genoa, Italy.
- Unit of Dermatology, San Bartolomeo Hospital, La Spezia, Italy.
- Unit of Dermatology, Civil Hospital of Imperia, Imperia, Italy.
ORCID-Profile: Martina Burlando
Zitieren
APA
Brunasso, A. M. G., Salvi, I., Sorbara, S., Muracchioli, A., De Col, E., Baldari, M., Parodi, A., Cozzani, E., & Burlando, M. (2024). Improvement of self‐administration experience with a new injection device: Real‐life experience with risankizumab in patients with psoriasis. Skin Research and Technology, 30(8). https://doi.org/10.1111/srt.13902
Vancouver
Brunasso AMG, Salvi I, Sorbara S, Muracchioli A, De Col E, Baldari M, et al. Improvement of self‐administration experience with a new injection device: Real‐life experience with risankizumab in patients with psoriasis. Skin Research and Technology. 2024;30(8). doi:10.1111/srt.13902
BibTeX
@article{Brunasso2024,
author = {Brunasso, Alexandra Maria Giovanna and Salvi, Ilaria and Sorbara, Stefania and Muracchioli, Andrea and De Col, Elena and Baldari, Manuela and Parodi, Aurora and Cozzani, Emanuele and Burlando, Martina},
title = {Improvement of self‐administration experience with a new injection device: Real‐life experience with risankizumab in patients with psoriasis},
journal = {Skin Research and Technology},
year = {2024},
volume = {30},
number = {8},
doi = {10.1111/srt.13902}
}
EUVIMED